# US 6,730,487 B2 · Surface plasmon resonance biosensor for measurement of anti-glycolipid antibody levels in neuropathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,487 B2
- Document ID: US6730487B2
- Status: Granted
- Kind: B2
- Application number: 09/825,572
- Filed: 2001-04-03
- Published: 2002-11-28
- Granted: 2004-05-04
- Earliest claimed: 2001-04-03
- Assignees: The Trustees of Columbia University in the City of New York
- Inventors: Norman Latov; Armin Alaedini
- Web page: https://patentgrep.com/patent/US6730487B2

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/6854: {Immunoglobulins}
- Y10S 436/805: Optical property
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention provides a method of detecting human antibodies in a sera solution. The invention also provides a method of quantitating anti-glycolipid antibody levels in solutions. The invention provides a method of diagnosing disease states, including neurological diseases, by quantitating a subject's antibody levels.

## Claims

### Claim 1

A method of detecting antibodies in a blood or blood derivative solution comprising:
a) contacting the blood or blood derivative solution with a ganglioside-coated surface of a sensor chip under conditions that permit the antibodies to bind to the ganglioside coating;
b) detecting the change in surface plasmon resonance signal of the sensor chip resulting from the antibodies binding to the ganglioside coating.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antigen is an anti-ganglioside antibody.

### Claim 3 (depends on 1)

The method of claim 1, wherein a control surface plasmon resonance value is subtracted from the surface plasmon resonance signal.

### Claim 4 (depends on 3)

The method of claim 3, wherein the control surface plasmon resonance value comprises the signal detected from the surface of the sensor chip coated with a selected control antigen, wherein the chip is also alternatively exposed to the solution being evaluated for anti-antigen antibodies.

### Claim 5 (depends on 4)

The method of claim 4, wherein the control antigen is Ganglioside GM2.

### Claim 6 (depends on 1)

The method of claim 1, wherein the surface plasmon resonance signal is detected from the surface of the sensor chip coated with ganglioside GM1.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sensor chip comprises a glass slide coated with a gold film covalently linked to a methyl dextran layer.

### Claim 8 (depends on 1)

The method of claim 1, wherein the surface plasmon resonance signal is detected using an optical detector.

### Claim 9 (depends on 1)

The method of claim 1, wherein the solution is human sera.

### Claim 10 (depends on 1)

A method of claim 1, wherein the surface plasmon resonance signal is increased by washing the solution from the surface of the sensor chip and applying a second solution containing a secondary antibody to the surface.

### Claim 11

A method of determining whether a subject is suffering from a neurological disease comprising:
a) contacting the solution with a sensor chip comprising a ganglioside coated surface under conditions that permit anti-ganglioside antibodies to bind to the ganglioside coating and the sensor chip to emit a surface plasmon resonance signal; and
b) detecting a change in the surface plasmon resonance signal emitted by the sensor chip so as to thereby detect the binding of the antibodies to the ganglioside coating,
wherein detection of the change in surface plasmon resonance signal indicates the subject is suffering from the neurological disease.

### Claim 12 (depends on 11)

The method of claim 11, wherein the disease is Guillian-Barré syndrome, motor neuropathy, peripheral neuropathy or an autoimmune neuropathy.
